RFP 739-SL3800457 Custom Synthesize Antibody-Drug Conjugates

Texas Tech University Health Sciences Center is seeking a qualified vendor to design, manufacture, and deliver custom‑synthesized antibody‑drug conjugates (ADCs) that incorporate the Center’s proprietary c‑MYC inhibitor payload. The contractor will be responsible for selecting appropriate linker chemistries, performing site‑specific or stochastic conjugation to achieve target drug‑to‑antibody ratios, purifying the final product, and providing full analytical documentation. The effort is phased (feasibility, pilot, scale‑up) and culminates in a stable ADC product with accompanying certificates of analysis and a final project report. • Develop conjugation strategy (linker, DAR, payload integration) for the c‑MYC inhibitor. • Execute pilot‑scale synthesis, characterize product (DAR, purity, mass spec, endotoxin). • Scale‑up to deliver final ADC quantity, provide CoA and comprehensive reporting. • Submit pricing, HUB subcontracting plan, signed W‑9, and proposer contact details by the May 26 2026 deadline.